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Abstract 
Continuous pharmaceutical manufacturing (CPM) has the potential to attain several 
technical and operational economic benefits compared to the currently prevalent batch 
production paradigm. Despite the variety of demonstrated continuous flow syntheses of 
active pharmaceutical ingredients (APIs), the limited number of cost-effective 
continuous separations is a bottleneck to end-to-end CPM. Establishing promising APIs 
for integrated CPM is paramount. (S)-Warfarin is an anticoagulant API whose 
continuous flow synthesis features a single reaction with high enantiomeric selectivity 
followed by liquid-liquid extraction (LLE). This work describes the steady-state process 
modelling and technoeconomic optimisation for the upstream CPM of (S)-warfarin, 
implementing reactor design and LLE solvent comparison for purification. Ethyl 
acetate, isopropyl acetate, isobutyl acetate, 1-heptanol, 1-octanol and heptane are 
candidate LLE solvents. Reported reaction conversions and computed LLE efficiencies 
allow mass balance calculation and total cost estimation to establish promising LLE 
solvents. The nonlinear optimisation problem is formulated for total cost minimisation. 
Liquid-liquid phase equilibria, API phase compositions and solubilities for LLE design 
are implemented via surrogate polynomials based on extensive UNIFAC modelling; 
API recovery rates are calculated via detailed mass transfer correlations. The 
methodology used here screens optimum process configurations to achieve a 
technoeconomically optimal design for a continuous (S)-warfarin manufacturing plant. 
 
Keywords: Continuous Pharmaceutical Manufacturing (CPM), (S)-warfarin. 
1. Introduction 
Continuous pharmaceutical manufacturing (CPM) is a key area of green chemistry 
research with the potential for significant technical, operational and economic benefits 
over currently prevalent batch manufacturing methods (Koenig and Dillon, 2017). 
Despite the numerous demonstrations of continuous flow syntheses (Britton and Raston, 
2017) towards active pharmaceutical ingredients (APIs), including end-to-end 
production campaigns (Adamo et al., 2016), only certain synthetic routes benefit from 
continuous operation (Hartman et al., 2011) and the lack of demonstrated continuous 
purification and separation methods integrated in CPM plants is an important obstacle 
(Bana et al., 2017). Establishing promising APIs for CPM application and screening for 
those with the highest likelihood of success is imperative for the elucidation of potential 
process configurations and successful implementation of continuous manufacturing 
routes (Teoh et al., 2015), and process modelling is critical in performance evaluation. 
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(S)-Warfarin is an anticoagulant API, commonly known as Coumadin®, commonly used 
for the treatment of deep vein thrombosis and pulmonary embolism (Porter, 2015). The 
continuous flow synthesis of (S)-warfarin features a single reaction and subsequent 
liquid-liquid extraction (LLE) process (Porta et al., 2015). Comparison of different 
conceptual separation process alternatives is essential for establishing cost-effective, 
materially efficient designs for upstream CPM configurations. Screening of candidate 
continuous LLE configurations for CPM of this API has yet to be conducted; process 
modelling, simulation and optimisation of continuous separation processes are valid 
alternatives to laborious experimental efforts for rapid design space investigation to 
elucidate technically feasible and economically viable processes (Jolliffe et al., 2018).  
Here, we implement steady-state process modelling and nonlinear optimisation for the 
upstream CPM of (S)-warfarin, including continuous flow synthesis and LLE. 
Flowsheet development based upon the published continuous synthetic route and a 
conceptual continuous LLE process are presented, comparing various separation 
solvents. Thermodynamic models for liquid-liquid phase composition and API 
solubility prediction in non-ideal, multicomponent mixtures for LLE design are 
described. Nonlinear optimisation problem formulation for total cost minimisation are 
presented. Minimum total costs, optimal API recoveries and material efficiencies for 
different process configurations are compared to establish promising LLE solvents. 
2. Process Modelling and Nonlinear Optimisation 
 
2.1 Continuous Flow Synthesis and Process Flowsheet 
The flowsheet for the CPM of (S)-warfarin (API) is shown in Fig. 1 (Porta et al., 2015). 
The continuous flow synthesis of the API features the nucleophilic addition of 4-
hydroxy-coumarin with benzalacetone in the presence of trifluoroacetic acid (TFA) and 
a chiral amine catalyst at 75 °C in 1,4-dioxane, with a reported conversion of 61%. 
Aqueous HCl (10% w/w) is added to the reactor effluent before entering the LLE unit. 
Upon addition of the candidate LLE solvent, the process forms an organic (product) 
phase containing recovered API and an aqueous (waste) phase, between which API 
partitions. Several candidate separation solvents are compared for continuous LLE: 
ethyl acetate (EtOAc), isopropyl acetate (iPrOAc), isobutyl acetate (iBuOAc), 1-
heptanol (HepOH), 1-octanol (OcOH) and n-heptane (nHep), as per (Alder et al. (2016). 
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Figure 1: Process flowsheet for continuous (S)-warfarin production (Porta et al., 2015). 
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2.2 Separation Design and Thermodynamic Modelling 
Continuous separation (LLE) processes are modelled as single-stage mixer-settlers at 
TLLE = 20, 40, 60 °C and solvent feed rates r = 1–4 (mass basis). The rate of API 
recovery, ḟ, is described by Eq. 1. K is the overall mass transfer coefficient, a is the 
volume-specific interfacial area, VLLE is the tank volume, and C* and C are the 
theoretical and equilibrium API concentrations in the product phase, respectively. ki and 
Shi are phase mass transfer coefficients and Sherwood numbers, respectively, DAPI is the 
API diffusivity, d32 is the dispersed phase Sauter mean droplet diameter, Sc is the 
Schmidt number, Fr is the Froude number, Eo is the Eotvos number, ϕ is the dispersed 
phase volume fraction, Rei is the impeller Reynolds’ number, di and dt are the impeller 
and tank diameters, respectively, We is the Weber number, Ni is the impeller rotation 
speed, ρc is the continuous phase density and σ is the interfacial surface tension 
(Skelland and Moetti, 1990).   f ̇  = KaVLLE�C*– C� (1)  K = �kc–1 + kd–1�–1 (2) 
Shd = kdd32DAPI,d  = 6.6 (3)  Shc = kcd32DAPI,c  = 1.25∙10–5Scc1/3Frc5/12Eo5/4ϕ–1/2Re2/3 � did32�2 �d32dt �1/2 (4) 
d32 = �0.052diWe-0.6 exp 4ϕ , We < 1030.390diWe-0.6 , We > 103   (5) 
We = di3Ni2ρc
σ
 (6) 
a = 6ϕ
d32
 (7) 
Phase compositions and mixture API solubilities are predicted via the UNIFAC model. 
LLE stage efficiencies (ELLE) allow calculation of actual product API concentrations 
from theoretical API concentrations in the product phase. 
ELLE = ((KaτLLE)–1 + 1)–1 (8) 
2.3 Nonlinear Optimisation Formulation 
The aim of the optimisation is to minimise the total cost objective function (Cost). 
min Cost = CapEx + � OpEx(1 + y)tτ
t = 1  (9) 
τLLE > 0 (10) 
1 < r < 4 (11) 
The discount rate (y = 5%) accounts for inflation and τ is the plant lifetime (20 years). 
Annual operation of 8,040 hours is considered. Optimisation decision variables are the 
LLE residence time (τLLE) and relative solvent feed rate (r). Capital (CapEx) 
expenditure includes battery limits installed costs, construction and working capital; 
operating expenditure (OpEx) is the sum of material costs, utilities and waste handling 
requirements (Schaber et al., 2011). Solvent recovery after LLE is assumed to be 70%; 
all material requirements are scaled to account for reaction and separation inefficiencies. 
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 3. Results and Discussion 
Minimum total costs for each LLE solvent and operating temperature are shown in Fig. 
2. The LLE solvent with the lowest minimum total costs is iBuOAc (293.87∙106 GBP, 
60 °C), followed by EtOAc (299.91∙106 GBP, 20 °C) and iPrOAc (299.93∙106 GBP, 60 
°C). These solvents perform comparably due to their similar molecular structures and 
polarities, inducing similar phase compositions and thus comparable API recoveries. 
This effect is also observed for HepOH and OcOH, which attain the next lowest total 
costs (339.43∙106 GBP and 324.54∙106 GBP, respectively) both operating at TLLE = 60 
°C. The poorest performance is attained via nHep (min cost = 350.52∙106 GBP, 60 °C). 
For most cases, increasing operating temperature leads to lower total costs due to the 
enhanced mass transfer (recovery) rates of API into the product phase, which requires 
shorter LLE tank residence times (lower CapEx) and material requirements (lower 
OpEx) to meet the plant capacity of 100 kg per annum. When nHep is implemented as a 
separation solvent, OpEx is significantly higher for all LLE operating temperatures (20, 
40, 60 °C) considered, due to the low API recoveries attainable in comparison to other 
separation solvents considered in this work (Fig. 3). In all process configurations, the 
solvent feed rate (r) is pushed to its lower bound (= 1). The solvent feed rate and its 
assumed recovery following LLE directly affects materials and waste treatment costs 
(key OpEx components). The sensitivity of total cost minima to varying solvent 
recovery can be readily compared using the methodological framework described here. 
 
 
Figure 2: Minimum total costs attainable for different continuous LLE configurations. 
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Attainable E-factors for all processes vary between 57–127; whilst these values are high 
in comparison to other manufacturing sectors (E < 0.1 for oil and gas processing), they 
are reasonable for pharmaceutical manufacturing processes (Roschangar et al., 2015). 
The E-factor variations are directly related to corresponding API recoveries; as API 
recovery increases, material requirements and waste (and thus the E-factor) decrease. 
Implementing the process configuration with the lowest total costs (iBuOAc, 60 °C) 
attains E = 58.4, which is very low in comparison to other configurations in this work. 
The described framework can be used to perform sensitivity analyses with respect to 
economic data (e.g. varying material prices, rates of interest for inflation) and other 
operational assumptions (e.g. achieved solvent recovery). It also allows the 
investigation of the effect of scaling plant capacity on total cost components and E-
factors, an essential consideration during process development. Candidate separation 
solvents investigated for application here have been selected based upon their suitability 
for LLE (i.e. exhibit rapid phase splitting with the process mixture and are considered 
suitable with respect to detailed EHS criteria). (S)-Warfarin is available in both liquid 
(dispersion) and solid (tablet) formulations, and thus consideration of crystallisation and 
downstream processing following the upstream CPM considered in this work. 
Consideration of the effects of LLE solvent choices and resulting API recoveries and 
purities in the organic product phase on the requirement for additional purification prior 
to further processing will aid LLE solvent selection. The methodology described in this 
work can be implemented for other APIs requiring continuous LLE, provided that 
kinetic and thermodynamic data are available for modelling and total cost minimisation. 
 
 
 
Figure 3: API recoveries and E-factors corresponding to total cost minima. 
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4. Conclusions 
This paper presents the systematic evaluation of six candidate separation solvents for 
the continuous liquid-liquid extraction (LLE) of (S)-warfarin following the 
experimentally demonstrated continuous flow synthesis (Porta et al., 2015). Comparison 
of minimum total costs via nonlinear optimisation with LLE solvent feed rate and tank 
residence time as decision variables establish promising candidate LLE solvents for the 
CPM of (S)-warfarin. Isobutyl acetate (iBuOAc) emerges as a promising candidate LLE 
solvent, attaining the lowest minimum total costs of 293.87∙106 GBP and a reasonable 
E-factor of 58.4, followed by ethyl acetate and isobutyl acetate. The considered alcohols 
(1-heptanol and 1-octanol) and n-heptane attain inferior performance (higher total costs) 
due to lower maximum (theoretical) API recoveries estimated by the UNIFAC method. 
The technoeconomic and environmental impact analyses presented in this work can 
inform the future design of CPM processes for this societally important API. 
Consideration of wider operating parameter sets and additional LLE solvents can be 
performed by adapting the existing framework, given the availability of required 
thermodynamic data and physical properties. Sensitivity analyses with respect to 
varying performance assumptions (e.g. varied attainable reaction and separation 
efficiencies upon scale up) and economic considerations (available solvent recovery, 
interest rates etc.) can be implemented within the framework and will add robustness to 
the presented results. Consideration of carrier and separation solvent combinations on 
subsequent upstream (e.g. crystallisation) and downstream (product formulation) unit 
operations is essential for successful implementation of a fully continuous process. 
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